-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The new crown pneumonia vaccine has played a key role in suppressing the spread of the epidemic.
Recently, researchers announced that after a large-scale vaccination, the three vaccines, BNT162b2, mRNA-1273 and Ad26.
COV2.
S, will reduce the hospitalization and hospitalization of severely ill high-risk patients with new coronary pneumonia.
The effect of ICU risk and emergency hospital admission risk for new coronary pneumonia
.
COV2.
S, on reducing the hospitalization and ICU risk of new coronary pneumonia in patients with severe high-risk patients and the risk of emergency hospital admission for new coronary pneumonia after a large-scale vaccination
.
Recently, researchers announced the effects of the three vaccines, BNT162b2, mRNA-1273 and Ad26.
Patients over the age of 50 who underwent nucleic acid testing for suspected new coronary pneumonia participated in the study, including 41552 inpatient cases in 187 hospitals and 21522 cases in 221 emergency centers from January 1 to June 22, 2021 Situation
.
According to the electronic health record and immunization registration status, the patient's vaccination status is obtained.
immunity
After completing the mRNA vaccination (14 days after the second vaccination), the vaccine's effectiveness in preventing SARS-CoV-2 infection leading to hospitalization was 89% (95% CI: 87-91), and its effectiveness in preventing ICU admission was 90%, the effectiveness of emergency department visits related to the prevention of new coronary pneumonia is 91%
.
The protective effects of BNT162b2 and mRNA-1273 vaccines range from 81% to 95% in people over 85 years of age, chronic diseases, and black or Hispanic people
After completing the mRNA vaccination (14 days after the second vaccination), the vaccine's effectiveness in preventing SARS-CoV-2 infection leading to hospitalization was 89% (95% CI: 87-91), and its effectiveness in preventing ICU admission was 90%, the effectiveness of emergency department visits related to the prevention of new coronary pneumonia is 91%
In the United States, after large-scale vaccination of the three vaccines BNT162b2, mRNA-1273 and Ad26.
In the United States, after mass vaccination of the three vaccines BNT162b2, mRNA-1273 and Ad26.
Original source:
Mark G.
Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings.
Leave a message here